iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.
iCo Therapeutics is currently engaged in partnership arrangements with organizations that include Isis Pharmaceuticals, MedImmune, Immune Pharmaceuticals and the University of British Columbia.
iCo Therapeutics acquired the exclusive, world-wide rights from partner Isis Pharmaceuticals Inc., to develop and commercialize iCo-007 for all disease indications.
iCo has a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME).
From partner MedImmune (a division of Astra Zeneca), iCo Therapeutics acquired the exclusive, world-wide rights to develop and commercialize iCo-008 for all disease indications. In 2010, iCo granted Immune Pharmaceuticals an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008. Immune Pharmaceuticals licensed the systemic rights to iCo-008 in June 2011. iCo retained worldwide exlcusive rights to all ocular applications of iCo-008. The partnership with the University of British Columbia resulted in the acquisition of the exclusive, worldwide rights to a novel oral formulation for Amphotericin B ( iCo-009 ) to be used for potential systemic fungal and parasitic infections.